JP5123922B2 - 融合糖タンパク質から成るエンベロープを有する逆行性輸送ウィルスベクター系 - Google Patents

融合糖タンパク質から成るエンベロープを有する逆行性輸送ウィルスベクター系 Download PDF

Info

Publication number
JP5123922B2
JP5123922B2 JP2009274156A JP2009274156A JP5123922B2 JP 5123922 B2 JP5123922 B2 JP 5123922B2 JP 2009274156 A JP2009274156 A JP 2009274156A JP 2009274156 A JP2009274156 A JP 2009274156A JP 5123922 B2 JP5123922 B2 JP 5123922B2
Authority
JP
Japan
Prior art keywords
gene
envelope
kit
vector
viral vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009274156A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011115077A (ja
JP2011115077A5 (enExample
Inventor
和人 小林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Science and Technology Agency
National Institute of Japan Science and Technology Agency
Original Assignee
Japan Science and Technology Agency
National Institute of Japan Science and Technology Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Science and Technology Agency, National Institute of Japan Science and Technology Agency filed Critical Japan Science and Technology Agency
Priority to JP2009274156A priority Critical patent/JP5123922B2/ja
Priority to EP10834471.4A priority patent/EP2508599B1/en
Priority to US13/511,873 priority patent/US9352052B2/en
Priority to PCT/JP2010/070136 priority patent/WO2011068019A1/ja
Publication of JP2011115077A publication Critical patent/JP2011115077A/ja
Publication of JP2011115077A5 publication Critical patent/JP2011115077A5/ja
Application granted granted Critical
Publication of JP5123922B2 publication Critical patent/JP5123922B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2009274156A 2009-12-02 2009-12-02 融合糖タンパク質から成るエンベロープを有する逆行性輸送ウィルスベクター系 Expired - Fee Related JP5123922B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2009274156A JP5123922B2 (ja) 2009-12-02 2009-12-02 融合糖タンパク質から成るエンベロープを有する逆行性輸送ウィルスベクター系
EP10834471.4A EP2508599B1 (en) 2009-12-02 2010-11-11 Retrograde transport viral vector system having envelope comprising fused glycoprotein
US13/511,873 US9352052B2 (en) 2009-12-02 2010-11-11 Retrograde transport viral vector system having envelope comprising fused glycoprotein
PCT/JP2010/070136 WO2011068019A1 (ja) 2009-12-02 2010-11-11 融合糖タンパク質から成るエンベロープを有する逆行性輸送ウィルスベクター系

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009274156A JP5123922B2 (ja) 2009-12-02 2009-12-02 融合糖タンパク質から成るエンベロープを有する逆行性輸送ウィルスベクター系

Publications (3)

Publication Number Publication Date
JP2011115077A JP2011115077A (ja) 2011-06-16
JP2011115077A5 JP2011115077A5 (enExample) 2012-05-17
JP5123922B2 true JP5123922B2 (ja) 2013-01-23

Family

ID=44114875

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009274156A Expired - Fee Related JP5123922B2 (ja) 2009-12-02 2009-12-02 融合糖タンパク質から成るエンベロープを有する逆行性輸送ウィルスベクター系

Country Status (4)

Country Link
US (1) US9352052B2 (enExample)
EP (1) EP2508599B1 (enExample)
JP (1) JP5123922B2 (enExample)
WO (1) WO2011068019A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5123922B2 (ja) 2009-12-02 2013-01-23 独立行政法人科学技術振興機構 融合糖タンパク質から成るエンベロープを有する逆行性輸送ウィルスベクター系
JP5216072B2 (ja) 2010-11-26 2013-06-19 独立行政法人科学技術振興機構 神経細胞特異的な逆行性輸送ベクター
EP2696847A1 (en) 2011-04-14 2014-02-19 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
US20150265710A1 (en) 2012-10-17 2015-09-24 Novo Nordisk A/S Fatty Acid Acylated D-Amino Acids for Oral Peptide Delivery
CN110981968B (zh) * 2019-12-17 2022-05-27 天康制药(苏州)有限公司 含有狂犬病病毒g蛋白的融合蛋白及其制备方法、应用和疫苗
CN112301002B (zh) * 2020-10-28 2023-01-13 中国科学院精密测量科学与技术创新研究院 一种减毒型狂犬病毒的制备方法与应用
CN117867029B (zh) * 2023-12-29 2024-12-20 复百澳(苏州)生物医药科技有限公司 一种狂犬亚型假病毒的制备方法及应用
WO2025209590A1 (zh) * 2024-04-03 2025-10-09 深圳市济因生物科技有限公司 一种病毒载体包装系统及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818209B1 (en) * 1998-05-22 2004-11-16 Oxford Biomedica (Uk) Limited Retroviral delivery system
US20030124146A1 (en) 2000-01-28 2003-07-03 Schnell Matthias J. Recombinant Rhabdoviruses as live-viral vaccines
US7238672B1 (en) * 2000-04-17 2007-07-03 Institut Pasteur Chimeric lyssavirus nucleic acids and polypeptides
JP2004517057A (ja) * 2000-11-03 2004-06-10 オックスフォード バイオメディカ（ユーケイ）リミテッド ベクターシステム
US20030026791A1 (en) * 2001-03-27 2003-02-06 Laurent Humeau Conditionally replicating vectors for inhibiting viral infections
JP2009034029A (ja) * 2007-08-01 2009-02-19 Japan Science & Technology Agency 逆行性輸送能を有するウィルスベクター系
JP5123922B2 (ja) 2009-12-02 2013-01-23 独立行政法人科学技術振興機構 融合糖タンパク質から成るエンベロープを有する逆行性輸送ウィルスベクター系

Also Published As

Publication number Publication date
EP2508599A4 (en) 2013-06-26
EP2508599B1 (en) 2016-04-20
US20120295964A1 (en) 2012-11-22
JP2011115077A (ja) 2011-06-16
EP2508599A1 (en) 2012-10-10
US9352052B2 (en) 2016-05-31
WO2011068019A1 (ja) 2011-06-09

Similar Documents

Publication Publication Date Title
JP5123922B2 (ja) 融合糖タンパク質から成るエンベロープを有する逆行性輸送ウィルスベクター系
Kato et al. Efficient gene transfer via retrograde transport in rodent and primate brains using a human immunodeficiency virus type 1-based vector pseudotyped with rabies virus glycoprotein
Desmaris et al. Production and neurotropism of lentivirus vectors pseudotyped with lyssavirus envelope glycoproteins
JP4861314B2 (ja) 非組み込み型且つ非複製型組換えレンチウイルス、その調製および使用
Baekelandt et al. Characterization of lentiviral vector-mediated gene transfer in adult mouse brain
Zufferey et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
Cronin et al. Altering the tropism of lentiviral vectors through pseudotyping
Carpentier et al. Enhanced pseudotyping efficiency of HIV-1 lentiviral vectors by a rabies/vesicular stomatitis virus chimeric envelope glycoprotein
US10596264B2 (en) Peptides with viral infection enhancing properties and their use
Kobayashi et al. Altering entry site preference of lentiviral vectors into neuronal cells by pseudotyping with envelope glycoproteins
Loewen et al. Lentiviral vectors
JP5216072B2 (ja) 神経細胞特異的な逆行性輸送ベクター
JP2009034029A (ja) 逆行性輸送能を有するウィルスベクター系
EP1333863A2 (en) Vector system for transducing th positive neurons
US7749973B2 (en) Methods of gene transfer to astrocytes with mokola virus pseudotyped lentivirus vectors
US20220228169A1 (en) Small ruminant lentivirus vector
Trabalza et al. Enhanced central nervous system transduction with lentiviral vectors pseudotyped with RVG/HIV-1gp41 chimeric envelope glycoproteins
US8278284B2 (en) Therapeutic agents for diseases associated with apoptotic degeneration in ocular tissue cells that use SIV-PEDF vectors
Liehl et al. Simian immunodeficiency virus vector pseudotypes differ in transduction efficiency and target cell specificity in brain
Molina et al. A synthetic Rev-independent bovine immunodeficiency virus-based packaging construct
Eleftheriadou et al. Lentiviral vectors for gene delivery to the nervous system
JP4766297B2 (ja) 非ウィルス由来のエンハンサーと、ｃＰＰＴと、ＣＴＳとを含むことを特徴とするベクター
Kato et al. Highly efficient retrograde gene transfer for genetic treatment of neurological diseases
WO2004044157A2 (en) Gp64-pseudotyped vectors and uses thereof
Segall et al. RNA VECTORS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120326

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20120326

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20120501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120605

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121023

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121026

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151102

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5123922

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees